Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Bought by FNY Investment Advisers LLC

FNY Investment Advisers LLC increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 25.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 121,654 shares of the company’s stock after buying an additional 25,000 shares during the quarter. FNY Investment Advisers LLC’s holdings in Ginkgo Bioworks were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DNA. ARK Investment Management LLC raised its holdings in shares of Ginkgo Bioworks by 3.0% in the 2nd quarter. ARK Investment Management LLC now owns 169,749,527 shares of the company’s stock worth $315,734,000 after purchasing an additional 4,992,542 shares during the period. BlackRock Inc. grew its stake in Ginkgo Bioworks by 7.7% during the first quarter. BlackRock Inc. now owns 50,664,080 shares of the company’s stock worth $67,383,000 after buying an additional 3,608,124 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Ginkgo Bioworks by 13.5% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 42,596,595 shares of the company’s stock worth $56,653,000 after purchasing an additional 5,082,277 shares during the period. Nikko Asset Management Americas Inc. boosted its position in shares of Ginkgo Bioworks by 13.5% in the first quarter. Nikko Asset Management Americas Inc. now owns 42,596,595 shares of the company’s stock worth $55,802,000 after buying an additional 5,082,277 shares during the period. Finally, State Street Corp raised its holdings in shares of Ginkgo Bioworks by 5.8% during the 1st quarter. State Street Corp now owns 14,707,508 shares of the company’s stock valued at $19,560,000 after buying an additional 800,982 shares during the period. Institutional investors and hedge funds own 56.84% of the company’s stock.

Ginkgo Bioworks Price Performance

NYSE:DNA traded down $0.03 during mid-day trading on Friday, reaching $1.93. The stock had a trading volume of 29,806,547 shares, compared to its average volume of 20,169,718. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of -2.72 and a beta of 1.17. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $1.12 and a 1-year high of $3.52. The stock’s 50 day simple moving average is $2.06 and its two-hundred day simple moving average is $1.67.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Ginkgo Bioworks had a negative return on equity of 66.58% and a negative net margin of 375.48%. The business had revenue of $80.57 million during the quarter, compared to the consensus estimate of $70.41 million. Sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Reshma P. Shetty sold 37,650 shares of Ginkgo Bioworks stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $1.79, for a total value of $67,393.50. Following the completion of the transaction, the insider now directly owns 13,353,454 shares of the company’s stock, valued at approximately $23,902,682.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Ginkgo Bioworks news, insider Jason R. Kelly sold 100,000 shares of the business’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $1.70, for a total transaction of $170,000.00. Following the completion of the transaction, the insider now directly owns 9,194,680 shares of the company’s stock, valued at approximately $15,630,956. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Reshma P. Shetty sold 37,650 shares of the business’s stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $1.79, for a total value of $67,393.50. Following the transaction, the insider now owns 13,353,454 shares of the company’s stock, valued at $23,902,682.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,331,520 shares of company stock valued at $2,685,148. Company insiders own 15.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on DNA shares. Raymond James decreased their price target on Ginkgo Bioworks from $5.00 to $3.50 and set an “outperform” rating for the company in a report on Thursday, August 31st. The Goldman Sachs Group downgraded Ginkgo Bioworks from a “neutral” rating to a “sell” rating and lowered their target price for the company from $3.00 to $1.25 in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Ginkgo Bioworks currently has a consensus rating of “Hold” and a consensus target price of $3.75.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.